Koji Date

Nantan, 6290141, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Baseline neutrophil-to-lymphocyte ratio predicts survival time after the initiation of nintedanib in patients with interstitial lung disease.

Baseline neutrophil-to-lymphocyte ratio predicts survival time after the initiation of nintedanib in patients with interstitial lung disease.

Journal: BMC pulmonary medicine

Published: March 11, 2026

Efficacy and safety of nintedanib for older adults with idiopathic pulmonary fibrosis or progressive fibrosing interstitial lung disease: A multicenter retrospective study in Japan.

Efficacy and safety of nintedanib for older adults with idiopathic pulmonary fibrosis or progressive fibrosing interstitial lung disease: A multicenter retrospective study in Japan.

Journal: Respiratory investigation

Published: February 26, 2026

Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression.

Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria.

Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria.

Journal: Journal of cachexia, sarcopenia and muscle

Published: November 24, 2025

Prognostic factors in patients with interstitial lung disease treated with nintedanib: a multicenter retrospective study in Japan.

Prognostic factors in patients with interstitial lung disease treated with nintedanib: a multicenter retrospective study in Japan.

Journal: Scientific reports

Published: September 04, 2025

Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy.

Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy.

Journal: Translational lung cancer research

Published: July 28, 2025

Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.

Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.

Journal: International journal of clinical oncology

Published: May 05, 2025

Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations.

Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations.

Journal: Clinical lung cancer

Published: April 30, 2025

Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure.

Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure.

Journal: Targeted oncology

Published: April 08, 2025

Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.

Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.

Journal: Oncoimmunology

Published: December 16, 2024

Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.

Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 21, 2024

Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.

Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.

Journal: Investigational new drugs

Published: June 27, 2024

Showing 1-12 of 28

Last Updated: 09/26/2026